Benten BioSciences

Benten BioSciences is a private biotechnology company focused on developing novel small molecule therapeutics that target metabolic vulnerabilities in cancer. The company's lead research centers on the NAD+ biosynthetic pathway, specifically targeting the enzyme Nicotinic acid phosphoribosyltransferase (NAPRT). Their lead candidate, BBS-101, is designed to selectively kill tumor cells that are deficient in alternative NAD+ production routes, such as the de novo pathway. By utilizing a precision medicine approach, Benten BioSciences aims to treat specific subsets of oncology patients whose tumors exhibit these metabolic dependencies. The company is headquartered in the biotechnology hub of Maryland and leverages insights into cancer metabolism to develop first-in-class treatments.